On average, participants reported 18 to 19 migraine days a month and using pain meds on 15 to 16 days.
For 12 weeks, they were given 30 milligrams of atogepant twice daily; 60 mg once a day; or a placebo. Atogepant is agene-related peptide receptor antagonist, or CGRP inhibitor. CGRP is a protein that helps trigger migraines. Participants with medication overuse who took atogepant twice a day averaged three fewer migraine days a month and three fewerThose taking atogepant once a day had two fewer migraine days a month and two fewer headacheResearchers said similar results were seen in participants who were not overusing medications.
Among participants with overuse, 45% of those taking atogepant twice a day and 42% who took it once a day had at least a 50% reduction in average monthly migraine days compared to 25% among those taking the placebo, the study found. Researchers said the number of participants who met the criteria for overuse dropped by 62% in the group taking the drug twice a day. It dropped 52% in once-a-day users.eveloping rebound headache by reducing the use of pain medications," Goadsby said in a journal news release. "This could lead to an improved quality of life for those living with migraine.
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: Medscape - 🏆 386. / 55 Read more »
Source: Medscape - 🏆 386. / 55 Read more »
Source: RedMagDaily - 🏆 312. / 61 Read more »
Source: WebMD - 🏆 709. / 51 Read more »